Skip to main content
Monday, November 16, 2026Nov 16

FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong

FILE - Pharmaceuticals billionaire Dr. Patrick Soon-Shiong waves as he arrives in the lobby of Trump Tower in New York for a meeting with President-elect Donald Trump on Jan. 10, 2017. (AP Photo/Evan Vucci, File)
FILE - Pharmaceuticals billionaire Dr. Patrick Soon-Shiong waves as he arrives in the lobby of Trump Tower in New York for a meeting with President-elect Donald Trump on Jan. 10, 2017. (AP Photo/Evan Vucci, File)

WASHINGTON (AP) — Federal health officials posted a warning Tuesday about misleading statements made by biotech billionaire Dr. Patrick Soon-Shiong, who recently told podcast listeners that his company’s bladder cancer drug may be able to treat, cure or even prevent other types of cancers.

The warning letter from the Food and Drug Administration takes issue with a TV advertisement and a separate podcast episode promoting Anktiva, the lead product of ImmunityBio Inc. The drugmaker is one of several biotech firms acquired by Soon-Shiong, who also owns the Los Angeles Times.

Company shares fell more than 21% in trading Tuesday to close at $7.42 after the FDA letter posted online.

Anktiva was approved by the FDA in 2024 for patients with a hard-to-treat form of bladder cancer. ImmunityBio has been working to win FDA approval to expand the drug’s use to a number of other conditions, including forms of lung and pancreatic cancer.

Soon-Shiong’s controversial statements came during a January episode of “The Sean Spicer Show” podcast titled “Is the FDA blocking life-saving cancer treatments?”